Paramount+ Black Friday Deal Drops Monthly Plans Down to $2.99 for Movies, Shows & Live Sports
From Nov. 19 to Nov. 30, subscribers can get any Paramount+ monthly plan for just $2.99 per month, with access to hit entertainment and live sports.
Entities › name
857 headlines · 111 outlets · 2024-02-29 → 2026-11-19 · Wikipedia ↗ · 🔒 Follow
From Nov. 19 to Nov. 30, subscribers can get any Paramount+ monthly plan for just $2.99 per month, with access to hit entertainment and live sports.
PITTSBURGH — It appears the Pittsburgh Steelers’ receiver room has some help on the way. Michael Pittman Jr. (foot) was […]
The meeting in China with President Trump and Chinese leader Xi Jinping marked a coup for the Russian leader—but he has little concrete to show for it.
'Wicked,' 'Chicago,' 'Hamilton,' 'Schmigadoon!' and 'The Lost Boys' are among the shows participating.
Lina Khan, the former US antitrust enforcer who Mayor Zohran Mamdani tapped for a top economic development role, is putting her stamp on New York City’s approach to stoking growth and hiring.
Five-step framework and auto claim triage guide help carriers identify where claim-process friction is adding avoidable cost and delay MEMPHIS, Tenn., Nov. 19, 2026 /PRNewswire/ -- Rising auto claims severity can feel unprecedented, but Sedgwick has seen this pattern before. In the white...
GSMA Digital Africa Index 2026 finds seven more countries joining the continent's leading group for digital development and enabling policy CAPE TOWN, South Africa, Nov. 19, 2026 /PRNewswire/ -- Africa is making measurable progress on digital development and enabling policy, but turning...
ITV’s “fan favorite” content will remain free-to-air once the commercial broadcaster has been subsumed by Sky, according to one of the architects behind the £1.6B ($2.1B) deal. Nick Herm, who is Group Chief Operating Officer at Sky, scotched the idea that some of ITV’s biggest shows will be moved…
CARTISTEM, a stem-cell treatment for knee cartilage damage approved in South Korea, has completed a Japanese Phase 3 trial and begun a pivotal U.S. study, though FDA approval remains pending.